Brief: Lee's Pharmaceutical Says Got NMPA Approval For IND Application Of GCC-4401C
11/03/2021 15:32
March 11 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* GETS NMPA APPROVAL FOR IND APPLICATION OF GCC-4401C
* APPROVAL TO CONDUCT TRIALS FOR GCC-4401C AS POTENTIAL
TREATMENT
FOR CIRRHOTIC PATIENTS WITH NON-TUMORAL PORTAL VEIN THROMBOSIS
Source text for Eikon: urn:newsml:reuters.com:*:nHKS7bSpSl
Further company coverage: 0950.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals